High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER negative breast cancer

GERARDO GATTI1,7, COURTNEY BETTS2, DARÍO RCHA, MARIBEL NICOLA1, VERÓNICA GRUPE, CECILIA DITADA; NICOLAS G. NUÑEZ; EMILIANO ROSELLI; PAULA ARAYA, JEREMÍAS DUTTO, LUCIA BOFFELLI, ELMER FERNÁNDEZ, LISA M. COUSSENS, MARIANA MACCION

BREAST CANCER RESEARCH

BIOMED CENTRAL LTD

Lugar: Londres; Año: 2021

1465-5411

haracterization of breast cancer (BC) through the determination of conventional markers such as ER, PR, HER2 and Ki67 has been useful as a predictive and therapeutic tool. Also, assessment of tumor-infiltrating lymphocytes has been proposed as an important prognostic aspect to be considered in certain BC subtypes. However, there is still a need to identify additional biomarkers that could add precision in distinguishing therapeutic response of individual patients. To this end, we focused in the expression of Interferon regulatory factor 8 (IRF8) in BC cells. IRF8 is a transcription factor which plays a well determined role in myeloid cells and that seems to have multiple antitumoral roles: it has tumor suppressor functions; it acts downstream IFN/STAT1 , required for the success of some therapeutic regimes and its expression in neoplastic cells seems to depend on a cross talk between the immune contexture and the tumor cells. The goal of the present study was to examine the relationsh